EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pan-Cancer Computational Analysis of RKIP (PEBP1) and LKB1 (STK11) Co-Expression Highlights Distinct Immunometabolic Dynamics and Therapeutic Responses Within the Tumor Microenvironment

Evangelia Skouradaki, Apostolos Zaravinos iD, Maria Panagopoulou iD, Ekaterini Chatzaki iD, Nikolas Dovrolis iD, Stavroula Baritaki

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26157145 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Evangelia Skouradaki und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Experimental Oncology, Division of Surgery, School of Medicine, University of Crete, 71003 Heraklion, Greece. Hauptthemen laut MEDLINE: Tumor Microenvironment, Protein Serine-Threonine Kinases, Neoplasms, Phosphatidylethanolamine Binding Protein. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Special Research Fund Account of the University of Crete.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RKIP and LKB1, encoded by PEBP1 and STK11, respectively, have emerged as key regulators of cancer pathophysiology. However, their role in shaping tumor progression through modulation of the tumor microenvironment (TME) is not yet fully understood. To address this, we performed a comprehensive pan-cancer analysis using TCGA transcriptomic data across 33 cancer types, grouped by their tissue of origin. We investigated PEBP1/STK11 co-expression and its association with transcriptomic reprogramming in major TME components, including immune, mechanical, metabolic, and hypoxic subtypes. Our results revealed both positive and inverse correlations between PEBP1/STK11 co-expression and TME-related molecular signatures, which did not align with classical cancer categorizations. In a subset of tumors, PEBP1/STK11 co-expression was significantly associated with improved overall survival and reduced mortality (HR < 1). Notably, we predominantly observed inverse correlations with pro-inflammatory and immunosuppressive chemokines, immune checkpoints, extracellular matrix components, and key regulators of epithelial-to-mesenchymal transition. In contrast, we found positive associations with anti-inflammatory chemokines and their receptors. Importantly, PEBP1/STK11 co-expression was consistently linked to reduced expression of drug resistance genes and greater chemosensitivity across multiple tumor types. Our findings underscore the co-expression of PEBP1 and STK11 as a promising target for future studies aimed at elucidating its potential as a biomarker for prognosis and therapeutic response in precision oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentProtein Serine-Threonine KinasesNeoplasmsPhosphatidylethanolamine Binding ProteinHumansAMP-Activated Protein Kinase KinasesGene Expression Regulation, NeoplasticComputational BiologyBiomarkers, TumorTranscriptomePrognosis

Stichwörter der Autor:innen

LKB1RKIPcancertumor microenvironment

Substanzen

Protein Serine-Threonine KinasesSTK11 protein, humanAMP-Activated Protein Kinase KinasesPhosphatidylethanolamine Binding ProteinPEBP1 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Laboratory of Experimental Oncology, Division of Surgery, School of Medicine, University of Crete, 71003 Heraklion, Greece.
  • Cancer Genetics, Genomic and Systems Biology Group, Basic and Translational Cancer Research Center (BTCRC), 1516 Nicosia, Cyprus.
  • Department of Life Sciences, School of Sciences, European University Cyprus, 2404 Nicosia, Cyprus.
  • Laboratory of Pharmacology, Department of Medicine, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
  • Institute of Agri-Food and Life Sciences, Hellenic Mediterranean University Research Centre, 71410 Heraklion, Greece.

ORCID-Profile: Apostolos Zaravinos, Maria Panagopoulou, Ekaterini Chatzaki, Nikolas Dovrolis

Förderung

  • Special Research Fund Account of the University of Crete

Zitieren

APA

Skouradaki, E., Zaravinos, A., Panagopoulou, M., Chatzaki, E., Dovrolis, N., & Baritaki, S. (2025). Pan-Cancer Computational Analysis of RKIP (PEBP1) and LKB1 (STK11) Co-Expression Highlights Distinct Immunometabolic Dynamics and Therapeutic Responses Within the Tumor Microenvironment. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26157145

Vancouver

Skouradaki E, Zaravinos A, Panagopoulou M, Chatzaki E, Dovrolis N, Baritaki S. Pan-Cancer Computational Analysis of RKIP (PEBP1) and LKB1 (STK11) Co-Expression Highlights Distinct Immunometabolic Dynamics and Therapeutic Responses Within the Tumor Microenvironment. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26157145

BibTeX
@article{Skouradaki2025,
  author = {Skouradaki, Evangelia and Zaravinos, Apostolos and Panagopoulou, Maria and Chatzaki, Ekaterini and Dovrolis, Nikolas and Baritaki, Stavroula},
  title = {Pan-Cancer Computational Analysis of RKIP (PEBP1) and LKB1 (STK11) Co-Expression Highlights Distinct Immunometabolic Dynamics and Therapeutic Responses Within the Tumor Microenvironment},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26157145}
}
Kostenlos starten →